Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPh201 in Previous NAION
NCT03547206Phase 2Terminated
- Sponsor
- Regenera Pharma
- Start
- Jul 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RPh201 in non-arteritic anterior ischemic optic neuropathy (NAION), sponsored by Regenera Pharma. Started Jul 2018; status: terminated.
02
Drugs
RPh201
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NCT03547206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547206.